News

UB-612 is said to be the first multitope, synthetic peptide-based Covid-19 vaccine candidate. Under the terms of the deal, Aurobindo Pharma will leverage its existing development, commercial and

Anle138b is a disease-modifying treatment option for synucleinopathies, such as Multiple System Atrophy (MSA) and PD. The short-term Phase 1b study with PD patients will be conducted by

Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase designed to be used as subcutaneous (SC) injection. Phesgo integrates the same monoclonal antibodies as

Merck acquired MK-7110 through the acquisition of OncoImmune, a privately held, clinical-stage biopharmaceutical company. “Building upon the promising clinical findings to date for MK-7110, Merck is pleased to

With the latest deal, the companies now will deliver up to 200 million doses to the US. Both firms plan to supply the full 200 million doses to

Hyundai Bioscience stated that CNPharm teamed up with Dt&CRO, a Korean contract research organization (CRO), to process animal and clinical studies for this new COVID-19 injection drug. Hyundai

In July this year, the company revealed a potential two-pronged strategy for the treatment of Covid-19. First, preclinical cell culture experiments shown CRV431 reduced SARS-CoV-1 production of infectious

This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine earlier today. The EC granted this CMA

The deal, which covers commercial, clinical and research-stage oncology portfolio, consists of an upfront payment of $1.8bn. Agios is also eligible to secure up to $200m in regulatory